Literature DB >> 24274912

Eradication of carbapenem-resistant Enterobacteriaceae gastrointestinal colonization with nonabsorbable oral antibiotic treatment: A prospective controlled trial.

Ilana Oren1, Hannah Sprecher, Renato Finkelstein, Salim Hadad, Ami Neuberger, Keatam Hussein, Ayelet Raz-Pasteur, Noa Lavi, Elias Saad, Israel Henig, Netanel Horowitz, Irit Avivi, Noam Benyamini, Riva Fineman, Yishai Ofran, Nuhad Haddad, Jacob M Rowe, Tsila Zuckerman.   

Abstract

BACKGROUND: Carbapenem-resistant Enterobacteriaceae (CRE) are emerging. In attempt to eradicate CRE colonization, we conducted a semirandomized, prospective, controlled trial using oral nonabsorbable antibiotics.
METHODS: Consecutive hospitalized CRE carriers were studied. Patients whose rectal isolates were gentamicin sensitive but colistin resistant were treated with gentamicin. Patients whose isolates were colistin sensitive but gentamicin resistant were treated with colistin. Patients whose isolates were sensitive to both drugs were randomized to 3 groups of oral antibiotic treatment: gentamicin, colistin, or both. Patients whose isolates were resistant to both drugs, and those who did not consent, were followed for spontaneous eradication.
RESULTS: One hundred fifty-two patients were included; 102 were followed for spontaneous eradication for a median duration of 140 days (controls), and 50 received 1 of the 3 drug regimens: gentamicin, 26; colistin, 16; both drugs, 8, followed for a median duration of 33 days. Eradication rates in the 3 treatment groups were 42%, 50%, and 37.5%, respectively, each significantly higher than the 7% spontaneous eradication rate in the control group (P < .001, P < .001, and P = .004, respectively) with no difference between the regimens. No significant adverse effects were observed.
CONCLUSION: Oral antibiotic treatment with nonabsorbable drugs to which CRE is susceptible appears to be an effective and safe for eradication of CRE colonization and, thereby, may reduce patient-to-patient transmission and incidence of clinical infection with this difficult-to-treat organism.
Copyright © 2013 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  Colistin; Gentamicin; Rectal carriage; SDD

Mesh:

Substances:

Year:  2013        PMID: 24274912     DOI: 10.1016/j.ajic.2013.04.018

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  25 in total

1.  Management of carbapenem resistant Klebsiella pneumoniae infections in stem cell transplant recipients: an Italian multidisciplinary consensus statement.

Authors:  Corrado Girmenia; Claudio Viscoli; Alfonso Piciocchi; Laura Cudillo; Stefano Botti; Antonio Errico; Loredana Sarmati; Fabio Ciceri; Franco Locatelli; Maddalena Giannella; Matteo Bassetti; Carlo Tascini; Letizia Lombardini; Ignazio Majolino; Claudio Farina; Francesco Luzzaro; Gian Maria Rossolini; Alessandro Rambaldi
Journal:  Haematologica       Date:  2015-04-10       Impact factor: 9.941

2.  Faecal microbiota transplant: a novel biological approach to extensively drug-resistant organism-related non-relapse mortality.

Authors:  A J Innes; B H Mullish; F Fernando; G Adams; J R Marchesi; J F Apperley; E Brannigan; F Davies; J Pavlů
Journal:  Bone Marrow Transplant       Date:  2017-07-17       Impact factor: 5.483

3.  Oral gentamicin gut decontamination for prevention of KPC-producing Klebsiella pneumoniae infections: relevance of concomitant systemic antibiotic therapy.

Authors:  Carlo Tascini; Francesco Sbrana; Sarah Flammini; Enrico Tagliaferri; Fabio Arena; Alessandro Leonildi; Ilaria Ciullo; Francesco Amadori; Antonello Di Paolo; Andrea Ripoli; Russell Lewis; Gian Maria Rossolini; Francesco Menichetti
Journal:  Antimicrob Agents Chemother       Date:  2014-01-13       Impact factor: 5.191

Review 4.  Multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant Enterococcus: Three major threats to hematopoietic stem cell transplant recipients.

Authors:  Michael J Satlin; Thomas J Walsh
Journal:  Transpl Infect Dis       Date:  2017-10-25       Impact factor: 2.228

Review 5.  Risk of infection following colonization with carbapenem-resistant Enterobactericeae: A systematic review.

Authors:  Jessica Tischendorf; Rafael Almeida de Avila; Nasia Safdar
Journal:  Am J Infect Control       Date:  2016-02-15       Impact factor: 2.918

Review 6.  Clinical Pharmacokinetics and Pharmacodynamics of Colistin.

Authors:  Nicolas Grégoire; Vincent Aranzana-Climent; Sophie Magréault; Sandrine Marchand; William Couet
Journal:  Clin Pharmacokinet       Date:  2017-12       Impact factor: 6.447

7.  The pros, cons, and unknowns of search and destroy for carbapenem-resistant enterobacteriaceae.

Authors:  Prashini Moodley; Andrew Whitelaw
Journal:  Curr Infect Dis Rep       Date:  2015-06       Impact factor: 3.725

Review 8.  The growing threat of multidrug-resistant Gram-negative infections in patients with hematologic malignancies.

Authors:  Thomas M Baker; Michael J Satlin
Journal:  Leuk Lymphoma       Date:  2016-06-24

Review 9.  Decolonization in Prevention of Health Care-Associated Infections.

Authors:  Edward J Septimus; Marin L Schweizer
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

10.  Detection and characterization of carbapenemase-producing Enterobacteriaceae in wounded Syrian patients admitted to hospitals in northern Israel.

Authors:  A Lerner; E Solter; E Rachi; A Adler; H Rechnitzer; D Miron; L Krupnick; S Sela; E Aga; Y Ziv; A Peretz; K Labay; G Rahav; Y Geffen; K Hussein; O Eluk; Y Carmeli; M J Schwaber
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-11-18       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.